{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T04:55:30Z","timestamp":1693716930489},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"S3","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern Emerg Med"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1007\/s11739-012-0821-x","type":"journal-article","created":{"date-parts":[[2012,10,17]],"date-time":"2012-10-17T16:34:49Z","timestamp":1350491689000},"page":"227-231","source":"Crossref","is-referenced-by-count":7,"title":["Fabry disease: raising awareness of the disease among physicians"],"prefix":"10.1007","volume":"7","author":[{"given":"Francesca","family":"Carubbi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Bonilauri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,10,17]]},"reference":[{"key":"821_CR1","first-page":"3733","volume-title":"The metabolic and molecular bases of inherited diseases","author":"RJ Desnick","year":"2001","unstructured":"Desnick RJ, Ioannou YA, Eng CM (2001) Alpha-galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Kinzler KE, Vogelstein B (eds) The metabolic and molecular bases of inherited diseases, 8th edn. McGraw-Hill, New York, pp 3733\u20133774","edition":"8"},{"key":"821_CR2","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","volume":"34","author":"A Mehta","year":"2004","unstructured":"Mehta A, Ricci R, Widmer U et al (2004) Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest 34:236\u2013242","journal-title":"Eur J Clin Invest"},{"key":"821_CR3","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s10545-007-0521-2","volume":"30","author":"CM Eng","year":"2007","unstructured":"Eng CM, Fletcher J, Wilcox WR et al (2007) Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J Inherit Metab Dis 30:184\u2013192","journal-title":"J Inherit Metab Dis"},{"key":"821_CR4","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/GIM.0b013e31802d8321","volume":"9","author":"RY Wang","year":"2007","unstructured":"Wang RY, Lelis A, Mirocha J, Wilcox WR (2007) Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life. Genet Med 9:34\u201345","journal-title":"Genet Med"},{"key":"821_CR5","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ymgme.2007.09.013","volume":"93","author":"WR Wilcox","year":"2008","unstructured":"Wilcox WR, Oliveira JP, Hopkin RJ et al (2008) Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol Genet Metab 93:112\u2013128","journal-title":"Mol Genet Metab"},{"key":"821_CR6","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/504601","volume":"79","author":"M Spada","year":"2006","unstructured":"Spada M, Pagliardini S, Yasuda M et al (2006) High incidence of later-onset Fabry disease revealed by newborn screening. Am J Hum Genet 79:31\u201340","journal-title":"Am J Hum Genet"},{"key":"821_CR7","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1097\/01.ASN.0000124671.61963.1E","volume":"15","author":"P Kotanko","year":"2004","unstructured":"Kotanko P, Kramar R, Devrnja D et al (2004) Results of a nationwide screening for Anderson-Fabry disease among dialysis patients. J Am Soc Nephrol 15:1323\u20131329","journal-title":"J Am Soc Nephrol"},{"key":"821_CR8","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1016\/S0140-6736(05)67635-0","volume":"366","author":"A Rolfs","year":"2005","unstructured":"Rolfs A, Bottcher T, Zschiesche M et al (2005) Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet 366:1794\u20131796","journal-title":"Lancet"},{"key":"821_CR9","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s100380170088","volume":"46","author":"GA Ashley","year":"2001","unstructured":"Ashley GA, Shabbeer J, Yasuda M, Eng CM, Desnick RJ (2001) Fabry disease: twenty novel alpha-galactosidase A mutations causing the classical phenotype. J Hum Genet 46:192\u2013196","journal-title":"J Hum Genet"},{"key":"821_CR10","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1046\/j.1523-1755.2003.00160.x","volume":"64","author":"S Nakao","year":"2003","unstructured":"Nakao S, Kodama C, Takenaka T et al (2003) Fabry disease: detection of undiagnosed hemodialysis patients and identification of a \u201crenal variant\u201d phenotype. Kidney Int 64:801\u2013807","journal-title":"Kidney Int"},{"key":"821_CR11","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1056\/NEJM199508033330504","volume":"333","author":"S Nakao","year":"1995","unstructured":"Nakao S, Takenaka T, Maeda M et al (1995) An atypical variant of Fabry\u2019s disease in men with left ventricular hypertrophy. N Engl J Med 333:288\u2013293","journal-title":"N Engl J Med"},{"key":"821_CR12","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(08)61589-5","volume":"372","author":"YA Zarate","year":"2008","unstructured":"Zarate YA, Hopkin J (2008) Fabry\u2019s disease. Lancet 372:1427\u20131435","journal-title":"Lancet"},{"key":"821_CR13","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/j.1445-5994.2007.01366.x","volume":"37","author":"M Low","year":"2007","unstructured":"Low M, Nicholls K, Tubridy N et al (2007) Neurology of Fabry disease. Intern Med J 37:436\u2013447","journal-title":"Intern Med J"},{"key":"821_CR14","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.jpeds.2004.01.051","volume":"144","author":"RJ Desnick","year":"2004","unstructured":"Desnick RJ, Brady RO (2004) Fabry disease in childhood. J Pediatr 144:S20\u2013S26","journal-title":"J Pediatr"},{"key":"821_CR15","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1136\/bjo.2009.176651","volume":"94","author":"LE Allen","year":"2010","unstructured":"Allen LE, Cosgrave EM, Kersey JP, Ramaswami U (2010) Fabry disease in children: correlation between ocular manifestations, genotype and systemic clinical severity. Br J Ophthalmol 94:1602\u20131605","journal-title":"Br J Ophthalmol"},{"key":"821_CR16","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1399-0004.2004.00219.x","volume":"65","author":"C Whybra","year":"2004","unstructured":"Whybra C, Kampmann C, Krummenauer F et al (2004) The Mainz Severity Score Index: a new instrument for quantifying the Anderson-Fabry disease phenotype and the response of patients to enzyme replacement therapy. Clin Genet 65:299\u2013307","journal-title":"Clin Genet"},{"key":"821_CR17","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/j.1365-2362.2006.01702.x","volume":"36","author":"S Hegemann","year":"2006","unstructured":"Hegemann S, Hajioff D, Conti G et al (2006) Hearing loss in Fabry disease: data from the Fabry Outcome Survey. Eur J Clin Invest 36:654\u2013662","journal-title":"Eur J Clin Invest"},{"key":"821_CR18","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/j.jacc.2005.11.070","volume":"47","author":"M Pieroni","year":"2006","unstructured":"Pieroni M, Chimenti C, De Cobelli F et al (2006) Fabry\u2019s disease cardiomyopathy: echocardiographic detection of endomyocardial glycosphingolipid compartmentalization. J Am Coll Cardiol 47:1663\u20131671","journal-title":"J Am Coll Cardiol"},{"key":"821_CR19","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/eurheartj\/ehm153","volume":"28","author":"A Linhart","year":"2007","unstructured":"Linhart A, Kampmann C, Zamorano JL et al (2007) Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey. Eur Heart J 28:1228\u20131235","journal-title":"Eur Heart J"},{"key":"821_CR20","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1097\/GIM.0b013e3181bb05bb","volume":"11","author":"S Waldek","year":"2009","unstructured":"Waldek S, Patel MR, Banikazemi M, Lemay R, Lee P (2009) Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry. Genet Med 11:790\u2013796","journal-title":"Genet Med"},{"key":"821_CR21","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jns.2007.01.053","volume":"257","author":"DF Moore","year":"2007","unstructured":"Moore DF, Kaneski CR, Askari H, Schiffmann R (2007) The cerebral vasculopathy of Fabry disease. J Neurol Sci 257:258\u2013263","journal-title":"J Neurol Sci"},{"issue":"s2","key":"821_CR22","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/01.ASN.0000016684.07368.75","volume":"13","author":"J Alroy","year":"2002","unstructured":"Alroy J, Sabnis S, Kopp JB (2002) Renal pathology in Fabry disease. J Am Soc Nephrol 13(s2):134\u2013138","journal-title":"J Am Soc Nephrol"},{"key":"821_CR23","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s10545-007-0708-6","volume":"30","author":"AL Cole","year":"2007","unstructured":"Cole AL, Lee PJ, Hughes DA et al (2007) Depression in adults with Fabry disease: a common and under-diagnosed problem. J Inherit Metab Dis 30:943\u2013951","journal-title":"J Inherit Metab Dis"},{"key":"821_CR24","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1016\/S0140-6736(09)61493-8","volume":"374","author":"A Mehta","year":"2009","unstructured":"Mehta A, Beck M, Elliott P, On Behalf of the Fabry Outcome Survey Investigators et al (2009) Enzyme replacement therapy with agalsidase alfa in patients with Fabry\u2019s disease: an analysis of registry data. Lancet 374:1986\u20131996","journal-title":"Lancet"},{"key":"821_CR25","doi-asserted-by":"crossref","first-page":"338","DOI":"10.7326\/0003-4819-138-4-200302180-00014","volume":"38","author":"RJ Desnick","year":"2003","unstructured":"Desnick RJ, Brady R, Barranger J et al (2003) Fabry disease, an underrecognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 38:338\u2013346","journal-title":"Ann Intern Med"},{"key":"821_CR26","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/01.gim.0000237866.70357.c6","volume":"8","author":"CM Eng","year":"2006","unstructured":"Eng CM, Germain DP, Banikazem M et al (2006) Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med 8:539\u2013548","journal-title":"Genet Med"},{"key":"821_CR27","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ymgme.2009.10.178","volume":"99","author":"EH Giannini","year":"2010","unstructured":"Giannini EH, Mehta AB, Hilz MJ et al (2010) A validated disease severity scoring system for Fabry disease. Mol Genet Metab 99:283\u2013290","journal-title":"Mol Genet Metab"},{"key":"821_CR28","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ymgme.2010.06.002","volume":"101","author":"DA Hughes","year":"2010","unstructured":"Hughes DA, Ramaswami U et al (2010) Age adjusting severity scores for Anderson-Fabry disease. Mol Genet Metab 101:219\u2013227","journal-title":"Mol Genet Metab"},{"key":"821_CR29","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1038\/sj.ki.5000208","volume":"69","author":"F Breunig","year":"2006","unstructured":"Breunig F, Weidemann F, Strotmann J, Knoll A, Wanner C (2006) Clinical benefit of enzyme replacement therapy in Fabry disease. Kidney Int 69:1216\u20131221","journal-title":"Kidney Int"},{"key":"821_CR30","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/hrt.2006.104026","volume":"94","author":"DA Hughes","year":"2008","unstructured":"Hughes DA, Elliott PM, Shah J et al (2008) Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomized, double-blind, placebo-controlled clinical trial of agalsidase-alfa. Heart 94:153\u2013158","journal-title":"Heart"},{"key":"821_CR31","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1651-2227.2007.00029.x","volume":"96","author":"U Ramaswami","year":"2007","unstructured":"Ramaswami U, Wendt S, Pintos-Morell G et al (2007) Enzyme replacement therapy with agalsidase alfa in children with Fabry disease. Acta Paediatr 96:122\u2013127","journal-title":"Acta Paediatr"},{"key":"821_CR32","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.2165\/11318300-000000000-00000","volume":"69","author":"RM Schaefer","year":"2009","unstructured":"Schaefer RM, Tylki-Szyma\u0144ska A, Hilz MJ (2009) Enzyme replacement therapy for Fabry disease: a systematic review of available evidence. Drugs 69:2179\u20132205","journal-title":"Drugs"},{"key":"821_CR33","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2165\/00003495-200767030-00007","volume":"67","author":"GM Keating","year":"2007","unstructured":"Keating GM, Simpson D (2007) Agalsidase Beta: a review of its use in the management of Fabry disease. Drugs 67:435\u2013455","journal-title":"Drugs"},{"key":"821_CR34","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1111\/j.1523-1755.2004.00514.x","volume":"65","author":"R Mignani","year":"2004","unstructured":"Mignani R, Panichi V, Giudicissi A et al (2004) Enzyme replacement therapy with agalsidase beta in kidney transplant patients with Fabry disease: a pilot study. Kidney Int 65:1381\u20131385","journal-title":"Kidney Int"},{"key":"821_CR35","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jpeds.2007.09.007","volume":"152","author":"JE Wraith","year":"2008","unstructured":"Wraith JE, Tylki-Szymanska A, Guffon N et al (2008) Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease. J Pediatr 152:563\u2013570","journal-title":"J Pediatr"},{"key":"821_CR36","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1681\/ASN.2006080816","volume":"18","author":"DP Germain","year":"2007","unstructured":"Germain DP, Waldek S, Banikazemi M et al (2007) Sustained, long-term renal stabilization after 54\u00a0months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol 18:1547\u20131557","journal-title":"J Am Soc Nephrol"},{"key":"821_CR37","doi-asserted-by":"crossref","first-page":"e598","DOI":"10.1371\/journal.pone.0000598","volume":"2","author":"AC Vedder","year":"2007","unstructured":"Vedder AC, Linthorst GE, Houge G et al (2007) Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2\u00a0mg\/kg. PLoS One 2:e598","journal-title":"PLoS One"},{"key":"821_CR38","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1111\/j.1523-1755.2004.00924.x","volume":"66","author":"GE Linthorst","year":"2004","unstructured":"Linthorst GE, Hollak CE, Donker-Koopman WE, Strijland A, Aerts JM (2004) Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta. Kidney Int 66:1589\u20131595","journal-title":"Kidney Int"},{"key":"821_CR39","doi-asserted-by":"crossref","first-page":"C1076","DOI":"10.1152\/ajpcell.00426.2005","volume":"290","author":"GH Yam","year":"2006","unstructured":"Yam GH, Bosshard N, Zuber C, Steinmann B, Roth J (2006) Pharmacological chaperone corrects lysosomal storage in Fabry disease caused by trafficking-incompetent variants. Am J Physiol Cell Physiol 290:C1076\u2013C1082","journal-title":"Am J Physiol Cell Physiol"},{"issue":"Suppl 1","key":"821_CR40","first-page":"S111","volume":"47","author":"DP Germain","year":"2009","unstructured":"Germain DP, Fan JQ (2009) Pharmacological chaperone therapy by active-site specific chaperones in Fabry disease: in vitro and preclinical studies. Int J Clin Pharmacol Therapy 47(Suppl 1):S111\u2013S117","journal-title":"Int J Clin Pharmacol Therapy"},{"key":"821_CR41","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1172\/JCI9711","volume":"105","author":"A Abe","year":"2000","unstructured":"Abe A, Gregory S, Lee L et al (2000) Reduction of globotriaosylceramide in Fabry disease mice by substrate deprivation. J Clin Invest 105:1563\u20131571","journal-title":"J Clin Invest"}],"container-title":["Internal and Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-012-0821-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11739-012-0821-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-012-0821-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,4]],"date-time":"2019-07-04T19:16:44Z","timestamp":1562267804000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11739-012-0821-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":41,"journal-issue":{"issue":"S3","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["821"],"URL":"https:\/\/doi.org\/10.1007\/s11739-012-0821-x","relation":{},"ISSN":["1828-0447","1970-9366"],"issn-type":[{"value":"1828-0447","type":"print"},{"value":"1970-9366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10]]}}}